BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 獨立非執行董事 林曉波先生 段濤博士 涂雷先生 董事會下設三個委員會。下表詳列該等委員會的成員。 | | 董事會委員會 | 審計 | 薪酬 | 提名 | | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | | 譚錚先生 | | – | – | C | | 李思睿先生 | | – | – | – | | 李明秋女士 | – | | – | M | | Deng Feng先生 | | – | – | – | | 林曉波先生 | | C | M | M | | 段濤博士 | | M | M | M | | 涂雷先生 | | M | C | M | 董事名單與其角色及職能 腦動極光醫療科技有限公司（「本公司」）董事會（「董事會」）成員載列如下。 執行董事 譚錚先生 （董事會主席） 非執行董事 李思睿先生 李明秋女士 Deng Feng先生 （股份代號：6681） 附註： C－相關董事會委員會的主席 M－相關董事會委員 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 獨立非執行董事及董事會委員會組成變動 及 委任首席執行官 獨立非執行董事變動 腦動極光醫療科技有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事 （「董事」）會（「董事會」）宣佈，李月中先生（「李先生」）由於其他工作安排及個人 時間安排，已辭任獨立非執行董事，自2025年11月18日起生效。 李先生已確認其與董事會並無意見分歧，且概無有關其辭任的事宜須敦請本公司 股東或香港聯合交易所有限公司（「聯交所」）垂注。 董事會欣然宣佈，自2025年11月18日起，塗雷先生（「塗先生」）已獲委任為獨立 非執行董事。 1 塗先生的履歷詳情載列如下： 塗雷先生，44歲，在企業融資及企業管理方面擁有豐富經驗。 塗先生於2005年4月至2016年9月在渣 ...

Core Viewpoint - The brain-computer interface (BCI) concept stocks in the Hong Kong market have shown strong performance, driven by the advancement of a domestically developed implantable wireless BCI system entering a special review process by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this technology [1][2]. Group 1: Market Performance - Brain动极光-B has increased by over 9%, with a latest price of 6.960 and a total market capitalization of 8.813 billion [2] - 微创脑科学 has risen by over 4%, with a latest price of 11.880 and a total market capitalization of 6.843 billion [2] - 南京熊猫电子股份 has gained nearly 3%, with a latest price of 5.140 and a total market capitalization of 4.697 billion [2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive BCI product to enter the "green channel" for innovative medical devices in China, indicating a key transition from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing a significant rise, driven by advancements in technology and supportive regulatory developments in China [1] Group 1: Market Performance - Brain-machine concept stocks have collectively surged, with notable increases: Brainhole Aurora (06681) up 8.49% to HKD 6.9, Nanjing Panda Electronics (00553) up 3.2% to HKD 5.16, and Microneuroscience (02172) up 4.39% to HKD 11.9 [1] Group 2: Regulatory Developments - On November 11, Shanghai Ladder Medical Technology Co., Ltd.'s "implantable wireless brain-machine interface system" entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA), marking it as the first invasive brain-machine interface product to enter this "green channel" in China [1] - The NMPA has also released the YY/T 1987—2025 standard for medical devices utilizing brain-machine interface technology, indicating a formalization of industry standards [1] Group 3: Industry Outlook - Dongwu Securities expresses optimism regarding the domestic policy support and accelerated clinical and commercial progress in the brain-machine interface industry [1] - Huafu Securities notes that advancements in brain science, artificial intelligence, medicine, cognitive neuroscience, and psychology are enriching the scope of brain-machine interfaces, highlighting multiple advantages for the development of this industry in China [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 USD | | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000,000 USD | | 0.0000001 | USD | | 50,000 ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

Core Insights - The stock of Brain Dynamics Aurora-B (06681) surged over 14%, reaching HKD 8.5 with a trading volume of HKD 311 million [1] Industry Developments - The Minister of Industry and Information Technology, Li Lecheng, emphasized the need to cultivate emerging industries and create new momentum during the 25th China International Industry Fair, focusing on technological innovation and the establishment of new pillar industries [1] - The National Medical Products Administration has approved the first medical device standard for brain-computer interface technology, which will be implemented on January 1, 2026, laying the foundation for the high-quality development of the brain-computer interface medical device industry [1] Company Highlights - Brain Dynamics Aurora's core product is a brain function information management platform software system, recognized as China's first regulatory-approved digital therapy product for cognitive impairment [2] - The company combines brain science with artificial intelligence, offering unique technological advantages such as virtual human technology and AI [2] - As the first company in China to develop a medical-grade digital therapy product for cognitive impairment, Brain Dynamics Aurora holds a first-mover advantage [2] - The core product is included in the provincial medical insurance reimbursement catalog across 30 provinces in China, enhancing product accessibility and market promotion [2] - The company has successfully established cognitive centers in over 120 hospitals in China, including several leading hospitals certified as "National Medical Centers" [2]

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (06681.HK) surged over 14% on September 30, reaching a price of 8.5 HKD [2] - The trading volume amounted to 311 million HKD [2]